Safety and efficacy of everolimus- versus sirolimus-eluting stents 5-year results from SORT OUT IV

Journal of the American College of Cardiology

Volumn 67, Issue 7, 2016, Pages 751-762

  Jensen, Lisette Okkels ^a   Thayssen, Per ^a   Christiansen, Evald Høj ^b   Maeng, Michael ^b   Ravkilde, Jan ^c   Hansen, Knud Nørregaard ^a   Hansen, Henrik Steen ^a   Krusell, Lars ^b   Kaltoft, Anne ^b   Tilsted, Hans Henrik ^c   Berencsi, Klara ^d   Junker, Anders ^a   Lassen, Jens Flensted ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

drug eluting stent(s); outcome; percutaneous coronary intervention; very late definite stent thrombosis

Indexed keywords

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEVICE SAFETY; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIROLIMUS ELUTING CORONARY STENT; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DENMARK; DRUG ELUTING STENT; FOLLOW UP; INCIDENCE; KAPLAN MEIER METHOD; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROSTHESIS DESIGN; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

CORONARY ARTERY DISEASE; DENMARK; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SIROLIMUS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84977456233     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.11.051     Document Type: Article

References (32)

1. M.C. Morice, P.W. Serruys, J.E. Sousa, and et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. J.W. Moses, M.B. Leon, J.J. Popma, and et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. G.W. Stone, S.G. Ellis, D.A. Cox, and et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
4. L.O. Jensen, H.H. Tilsted, P. Thayssen, and et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry EuroIntervention 5 2010 898 905
5. P.C. Smits, E. Kedhi, K.J. Royaards, and et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial) J Am Coll Cardiol 58 2011 11 18
6. G.W. Stone, A. Rizvi, K. Sudhir, and et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
7. L.O. Jensen, P. Thayssen, H.S. Hansen, and et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcomes IV (SORT OUT IV) Circulation 125 2012 1246 1255
8. K. Rasmussen, M. Maeng, A. Kaltoft, and et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
9. P.W. Serruys, S. Silber, S. Garg, and et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
10. T. Palmerini, G. Biondi-Zoccai, R.D. Della, and et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
11. H. Gada, A.J. Kirtane, W. Newman, and et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) JACC Cardiovasc Interv 6 2013 1263 1266
12. M. Maeng, H.H. Tilsted, L.O. Jensen, and et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial Lancet 383 2014 2047 2056
13. G.G. Stefanini, B. Kalesan, P.W. Serruys, and et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
14. M. Taniwaki, G.G. Stefanini, S. Silber, and et al. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) J Am Coll Cardiol 63 2014 1617 1625
15. W. Wijns, P.G. Steg, L. Mauri, and et al. Endeavor zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4 year results of the PROTECT randomized trial Eur Heart J 35 2014 2812 2820
16. S. Windecker, P.W. Serruys, S. Wandel, and et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
17. L.O. Jensen, P. Thayssen, M. Maeng, and et al. Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial J Am Coll Cardiol Intv 7 2014 840 848
18. L.O. Jensen, P. Thayssen, H.H. Tilsted, and et al. Rationale and design of a randomized clinical comparison of everolimus-Eluting (Xience V/Promus) and sirolimus-Eluting (cypher select+) coronary stents in unselected patients with coronary heart disease Cardiology 116 2010 73 78
19. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
20. E.H. Christiansen, L.O. Jensen, P. Thayssen, and et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial Lancet 381 2013 661 669
21. T.A. Gooley, W. Leisenring, J. Crowley, and B.E. Storer Estimation of failure probabilities in the presence of competing risks: new representations of old estimators Stat Med 18 1999 695 706
22. G.D. Dangas, P.W. Serruys, D.J. Kereiakes, and et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 6 2013 914 922
23. D.E. Kandzari, L. Mauri, J.J. Popma, and et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 4 2011 543 550
24. L. Raber, L. Wohlwend, M. Wigger, and et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial Circulation 123 2011 2819 2828
25. P.W. Serruys, V. Farooq, B. Kalesan, and et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial J Am Coll Cardiol Intv 6 2013 777 789
26. P. Thayssen, L.O. Jensen, J.F. Lassen, and et al. The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation EuroIntervention 8 2012 591 598
27. G. Giustino, U. Baber, S. Sartori, and et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials J Am Coll Cardiol 65 2015 1298 1310
28. G.W. Stone, A. Rizvi, W. Newman, and et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
29. S.J. Brener, D.J. Kereiakes, C.A. Simonton, and et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial Am Heart J 166 2013 1035 1042
30. L. Thuesen, L.O. Jensen, H.H. Tilsted, and et al. Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology Clin Epidemiol 5 2013 357 361
31. O. Frobert, B. Lagerqvist, G.K. Olivecrona, and et al. Thrombus aspiration during ST-segment elevation myocardial infarction N Engl J Med 369 2013 1587 1597
32. M.W. Webster, and J.A. Ormiston Sorting out drug-eluting stents Lancet 375 2010 1060 1062